neurotrophic factor (BDNF), 30 and ciliary neurotrophic factor (CNTF), 4 that are able to support the survival and maintenance of dopaminergic neurons. Additionally, pilot studies investigating the direct delivery of GDNF into the brains of patients with PD have shown safety as well as some clinical improvement. 10, 23, 28 Other clinical trials have also sought to deliver neurotrophic support, including neurturin, 18, 19 to patients with PD. Nevertheless, strategies utilizing growth factor delivery raise additional questions, such as which growth factors should be used and how should they be obtained, delivered, and dosed (see Rodrigues et al. 25 ). Currently purified growth factors are very difficult to manufacture, and access is limited by substantial patent restrictions. As a way to overcome these obstacles, we designed an open-label safety study to investigate the use of an autologous source of cellular tissue from the peripheral nervous system, the Schwann cell, which has been shown to produce and express several important growth factors, including GDNF, 29 BDNF, 1 and neurotrophin-3 (NT-3). 13 Peripheral nerve grafts and purified Schwann cell transplants into the CNS have been extensively employed in animal and human studies. 3, 6, 11, 15, 17, 27, 33, 34 Furthermore, in rodents and primates, peripheral nerve grafts and Schwann cell transplants survive and release nerve growth factor (NGF) even up to 3 months after delivery. 16, 24 The central hypothesis of this study is that the harvesting of the peripheral nerve graft will initiate the production of growth factors through the injury response and that the transplanted graft will allow the Schwann cells to associate with the degenerating dopaminergic neurons and deliver the expressed growth factors to restore and maintain the injured neurons over time. In this paper we describe the delivery of a peripheral nerve graft to the substantia nigra and the subsequent safety and adverse event profile of the procedure.
We chose to investigate the safety and tolerability of peripheral nerve grafts in participants who had been selected clinically as good candidates for deep brain stimulation (DBS) surgery. There are several advantages to this approach. First, participants received the full benefit of the DBS therapy. The implant procedure and follow-up design was purposefully designed to not interfere with the DBS clinical application. Second, the graft implantation was performed at the time of DBS surgery and therefore did not require an additional surgical intervention. Third, DBS therapy was amenable to testing the effects of an intervention on the baseline components of PD. Although this approach has been proposed previously for investigating a gene therapy approach, 7, 26 it was not actually performed. Thus we report the first clinical study to involve the investigation of a surgical therapeutic intervention in combination with DBS therapy. Here we describe the surgical details, graft implant technique, and perioperative adverse event profile.
Methods

Clinical Trial Design
This study was designed as a 12-month, open-label, single-center, Phase I trial to assess safety and feasibility as the primary endpoints. It was registered with the ClinicalTrials.gov database (http://clinicaltrials.gov), and its registration number is NCT01833364. Additional efficacy data were collected and will be reported in a later, separate paper. The timeline of the trial design is shown in Fig.  1 . The study was approved by the University of Kentucky institutional review board, and informed consent was obtained from all study participants.
Patient Selection
Eight patients with a diagnosis of idiopathic PD, who had been selected and had provided consent for DBS of the subthalamic nucleus (STN), were subsequently informed about the study and then agreed to participate in the study and gave formal consent. Thus, agreeing to participate in the study had no influence on the decision to undergo DBS therapy. Inclusion criteria included an age of 40 to 75 years, symptomatic, idiopathic PD for longer than 5 years, and an ability to participate in all follow-up appointments. As part of the standard preoperative DBS protocol, participants were evaluated using the Unified Parkinson's Disease Rating Scale (UPDRS), both on and off medication, and underwent a formal neuropsychological evaluation. Preoperative imaging consisted of an MRI study for targeting purposes.
Safety and Feasibility
Participants were monitored for both perioperative and long-term postoperative adverse events. Clinical monitoring for this report includes the perioperative time points, the 1-month study evaluation visit, and all clinic visits in between. During this time period, adverse events were recorded from clinical reporting, chart review, and specific queries during the clinical visits. A postoperative 1.5-T MRI study was performed within 48 hours of the implantation surgery. Adverse events were categorized as either related to the graft or graft procedure, DBS surgery or therapy, or not related to either surgical or therapeutic component. In addition, adverse events were categorized as mild, moderate, or severe, as defined in the Medical Dictionary for Regulatory Activities, version 11.0. Serious adverse events were designated as any event that resulted in death, disability, or prolonged or new hospitalization or that was life threatening or that required medical or surgical intervention.
Surgical Implantation
Participants were evaluated preoperatively with a targeting 1.5-or 3.0-T MRI. The cortical entry points, trajectories, and STN were targeted bilaterally using Brainlab software (IPlan 3.0 Stereotaxy). The graft cannula trajectory was calculated as a trajectory parallel to the stimulating lead trajectory. The DBS implantation was performed in 2 stages. The traditional staging of the surgeries was reversed 31 by first implanting the pulse generator and lead extensions and placing the bur holes, based on frameless neuronavigation (Brainlab), during general anesthesia. Once this was completed, the patients were repositioned for access to the sural nerve. Through a standard sural nerve biopsy incision, the sural nerve was exposed and transected proximally. Two silk ties were loosely secured to the proximal and distal end of the nerve, distal to the transection. A 1-cm tail was left on the ties, providing easy identification of the nerve during the harvesting procedure, which was performed during the second stage of the surgery, 3-5 days later. The incision was then closed.
The second stage was completed 3 to 5 days after the first. Participants were fitted with an Integra CRW (Cosman-Roberts-Wells) frame and localizer and a thin-cut CT scan was performed for targeting. Frame coordinates for the targets and trajectories were calculated based on image fusion sequences using IPlan 3.0 Stereotaxy (Brainlab). Initial STN targets were chosen visually based on susceptibility-weighted imaging sequences. Microelectrode recordings were performed using a single electrode. The inferior border of the STN was designated as the electrophysiological point where cells were no longer identified and the increase in baseline that is typically seen in the STN dropped back to background levels. In some cases, cells with profiles consistent with substantia nigra pars reticulata were identified. Stimulating electrodes (Medtronic, 3387) were placed with the distal contact at the ventral border of the STN. Electrode contacts were then tested for efficacy and side effects. The STN contralateral to the least symptomatic side was implanted first. Once testing was complete, the bur hole was filled with Hydroset (Stryker) and the electrode was secured to the skull, connected to the lead extension, and internalized.
After testing of the second electrode was complete, the electrode was secured to the skull using a mini-plate. The graft target zone was then calculated through a trajectory parallel to the stimulating electrode and approximately 3 mm posterior and lateral. A guide cannula (FHC Inc., 1.8-mm outer diameter) was then placed to target within the graft target zone. The target zone was designated to occupy a 5-mm space within the substantia nigra pars reticulata between 1 mm and 6 mm deep to the inferior border of the STN (Fig. 2) . The sural nerve incision was prepared and opened. The sural nerve was identified using the silk ties, and a 2-cm segment of nerve was harvested distal to the previous transection site. The nerve segment was then rinsed in sterile saline in a petri dish. The epineurium was removed sharply. The remaining fascicles were then cut transversely to produce a number of smaller segments approximately 1 mm in length. Five to six segments less than 1.5 mm in diameter were then loaded into the custom-made graft cannula through a side loading port and advanced to the distal end of the graft cannula using the flat-ended inner stylet (Fig. 3) . The stylet was then locked in place with set screws. The guide cannula was removed, and the graft cannula was placed to target through the same bur hole used for the stimulating electrode. The graft was deployed by releasing the inferior set screw and retracting the graft cannula 5 mm. After 2 minutes, the assembly was rotated in place several times to facilitate graft detachment from the assembly. The graft cannula assembly was then removed. The dura was covered with Durepair dura regeneration matrix (Medtronic) and the bur hole was filled with HydroSet. This sequencing was chosen so that the grafting procedure would not interfere with the DBS implantation.
Graft Cannula
The graft cannula design was based on a custom design modification of a standard guide cannula (lead insertion tube, FHC). The modifications included a side window proximal to the distal tip, an extended length to reach 6 mm below target for CRW specifications, and a modified, 2-set-screw locking coupler to stabilize the inner stylet with the outer cannula. This construction allows for the graft tissue to be deposited into brain parenchyma rather than being pushed in. The dimensions of the graft cannula are shown in Fig. 3 (upper) .
Postoperative Evaluation
After DBS and graft implantation, participants were admitted overnight and received a postoperative MRI to confirm electrode placement and to evaluate the region of the graft target zone. Additionally, stimulator programming was initiated during this time period. Participants were then followed clinically through routine postoperative visits, programming visits, and for their 1-month postoperative study visits. While the protocol includes additional study visits at 6, 9, and 12 months, this mid-study report focuses on the safety data through the 1st month time point for all 8 patients.
Results
Participant Profile
Eight participants (6 male and 2 female) were enrolled in the study (Table 1) . Neuropsychological evaluations demonstrated mild to moderate declines consistent with PD related changes and did not demonstrate any significant deterioration that would preclude them from the study.
Surgical Results
All 8 participants were successfully implanted with bi- lateral DBS electrodes and underwent the grafting procedure without any technical difficulties. The mean duration of time for bilateral DBS electrode and graft placement was 3 hours 51 minutes (SD 26 minutes), which is consistent with our previously reported surgery times.
31
Postoperative MR images showed accurate placements of all 16 DBS electrodes. There was no evidence of hemorrhage or edema around the electrodes. With respect to the graft target zone, there was no significant signal variability providing evidence for graft placement confirmation, significant edema, or hemorrhage (Fig. 4) .
Adverse Events
Reported adverse events (Table 2) were in line with profiles from DBS surgery. 22, 32 After the second stage of the surgery, 3 participants described a patch of numbness on the outer aspect of the foot.
Discussion
The primary objectives of this pilot study were to assess safety and feasibility of the grafting procedure along with tolerability of the graft. Although the concept of tissue implantation into the brain is not new, the issue of safety is critical in that this is the first clinical trial where grafts have been implanted in conjunction with DBS therapy.
With respect to the grafting procedure, we show that peripheral nerve tissue can be readily harvested, loaded into a cannula, and stereotactically deposited into the target site, with the procedure adding only 30-60 minutes. Concerning safety, none of the adverse events were attributable to the grafting procedure except for mild, transient numbness on the outer aspect of the foot where the sural nerve biopsy occurred. The adverse event profile is not different from that of nongrafting DBS procedures performed in our center (unpublished observations) or published reports. 12, 22, 32 With a cannula of a standard (1.8-mm) size, the overall risk of this procedure, compared with DBS surgery alone, can be estimated to be that of a single additional 
Characteristic
Mean ± SD Age in years 62.9 ± 9.2 PD duration in years 9.8 ± 3.9
l-Dopa equivalents* in mg/day 854 ± 556 UPDRS score Part III (motor symptoms) OFF 32.5 ± 9.7 ON 13.4 ± 9.7 Total ON 38.4 ± 13.1 PDQ-8 9.4 ± 4. cannula pass. Based on these findings, the results from this study provide direct evidence that graft implantation can be carried out at the same time as DBS implantation without significant risk to the recipient. There are several advantages to combining nerve graft delivery at the time of DBS surgery when performed as described here: 1) because the grafting procedure is performed after the implantation of the pulse generator, lead extensions, and DBS leads, the grafting procedure does not interfere with the DBS implantation procedure; 2) an additional surgery outside of the scheduled DBS procedures is not required; 3) participants supply their own tissue, which eliminates the potential for immune rejection that is present with other transplantation strategies. Because the grafting procedure used autologous grafts harvested and delivered during the same surgical procedure and the tissue was not chemically or genetically modified, the study did not have to comply with the requirements of the FDA regulations on tissue delivery.
Although the placement of the DBS electrodes could be confirmed with postoperative MRI, we found no significant or consistent MRI signal changes within the graft target region. This finding was somewhat unexpected in that we anticipated that the insertion of the cannula, in and of itself, into the region would lead to a consistent, identifiable increase in T2 signal on the MRI. One possible explanation is that the implanted graft, being solid tissue, negates the potential T2 signal change. Nevertheless, this grafting approach combined with DBS does present a limit on imaging with MR, as currently only 1.5-T MR images can be obtained with implanted DBS electrodes. Furthermore, while sural nerve grafts to the basal ganglia in nonhuman primates show extensive NGF-reactive Schwann cell survival 3 months after transplantation, 16 because the peripheral nerve tissue is not biologically or chemically modified, noninvasive tracking of graft survival is not possible. Assessing the viability of the graft over time remains one of the key limitations of this technique. For now, our approach to begin addressing issues of graft viability, factors that may enhance the viability, and functional assessments of the graft is to use animal studies to model the graft delivery and implantation. Currently, we lack a profile of the neurotrophic factors that are present in the sural nerve that is being implanted. To address this gap, we plan on employing proteomics to determine which neurotrophic factors may be present in harvested sural nerves. In the clinical domain, clinical outcome assessments will be the standard for measuring the success of the technique, while future studies may use other imaging modalities, such as PET, to further investigate the ability to track graft placement and/or function in vivo.
We chose the substantia nigra as our target for graft placement for several reasons. In addition to being the anatomical location of the dopaminergic neuron cell bodies, the substantia nigra is anatomically close to the STN, and this makes it an ideal target for minimizing risk following the DBS procedure. On the entry side, the substantia nigra as a target allowed us to use the same bur hole, without expansion, to target the STN for DBS lead implantation and the substantia nigra for graft placement. The dorsal border of the substantia nigra pars reticulata was identified based on preoperative MR targeting and the results of microelectrode recordings, but given that the cannula delivered the graft across a 6-mm span, it is possible that other regions of the substantia nigra were also reached. In PD, more cells are spared in the area of the pars reticulata than in the pars compacta, 5, 8 thus providing neurotrophic support to cells that may be spared or injured rather than cells that are dead could be a strategy for therapy.
While we have focused on the safety and feasibility of the operative and perioperative aspects of the technique in this report, we do think longer-term studies will be a necessary step on the way to fully establishing the safety of the procedure. We are continuing to collect safety data, which we plan to present in conjunction with the longerterm clinical outcome aspect of the study.
The strategy of combining the delivery of biological therapy with DBS surgery has been recently gaining momentum. 26 DBS therapy alone is insufficient for treating all of the symptoms associated with PD, and so, new therapies need to be developed to enhance the therapeutic benefits of DBS. The combined strategy outlined here presents one means of fulfilling this goal. In terms of clinical trial design, this strategy has the advantage of obviating the need for a sham surgical procedure while lowering trial-associated costs, since DBS surgery is a reimbursable procedure. The results from the delivery of peripheral nerve graft into the midbrain shown here may usher in a new approach for combining biologicals with DBS to provide multimodal therapy for PD.
Conclusions
We have accomplished our primary objectives of demonstrating the safety and feasibility of implanting peripheral nerve tissue in participants who are undergoing DBS surgery and treatment. We feel that this is an important, critical step as the first clinical study to combine the 2 approaches. However, we remain cautious, as the longer-term effects and safety of this combined procedure need to be further examined over the course of years, and of course, in a larger population. Thus far, the results provide ini- tial evidence that patients who elect to receive DBS therapy can be good candidates for neurorestorative therapies requiring invasive deployment, such as peripheral nerve grafts and in the future stem cell grafting, growth factor delivery, or gene therapy.
